ライフサイエンスコーパス: palliation

1 th, 7 converted after initial univentricular palliation).

2 nical Context The treatment goal for CRPC is palliation.

3 ally not the final stage of single-ventricle palliation.

4 ell transplantation, and supportive care and palliation.

5 2 surgical Norwood procedures before stage 2 palliation.

6 n delivery was similarly lower in the hybrid palliation.

7 cure, use of experimental therapies, and/or palliation.

8 diotherapy (WBRT) is a critical component of palliation.

9 ntage of patients with successful worst pain palliation.

10 n in mind allowing better and longer-lasting palliation.

11 have favorable outcomes after BDG or Fontan palliation.

12 modynamic stability and survival to stage II palliation.

13 cusing on the emergent methods of endoscopic palliation.

14 c disease, but chemotherapy can also provide palliation.

15 isease, this regimen provides at best modest palliation.

16 patients biliary drainage is the mainstay of palliation.

17 an interatrial communication before surgical palliation.

18 d's cancer deaths occur without treatment or palliation.

19 ial in selected patients early after Norwood palliation.

20 in the patient population undergoing Fontan palliation.

21 specified for patients with single ventricle palliation.

22 me overload characteristic of prior forms of palliation.

23 ies such as radioimmunotherapy and bone pain palliation.

24 or infections, improve function, or provide palliation.

25 es requiring aggressive treatment to achieve palliation.

26 ns of improving outcomes of single ventricle palliation.

27 ded to determine its exact role in bone pain palliation.

28 .5% for those discharged with univentricular palliation.

29 riod between stage I palliation and stage II palliation.

30 surgical interventions, rehabilitation, and palliation.

31 hypoplastic left heart syndrome after Fontan palliation.

32 ic left heart syndrome patients after Fontan palliation.

33 e prevention, treatment, rehabilitation, and palliation.

34 ne-third (220 of 675) had undergone previous palliation.

35 d be reserved for an analysis of post-Fontan palliation.

36 hemotherapy and surgery only if required for palliation.

37 y can be performed safely and offers durable palliation.

38 re treated by a staged approach with initial palliation (1.6 +/- 0.4 month; range, 1.5-2 months) foll

39 nd prednisone resulted in significantly more palliation (157 of 349 [45.0%] patients vs 47 of 163 [28

40 .0005) and faster palliation (median time to palliation 5.6 months [95% CI 3.7-9.2] vs 13.7 months [5

41 nging chemotherapy over treatment focused on palliation (67% vs. 64%; z = -1.79; p = .07) and to want

42 D but chose inotropes (15 patients), and for palliation (98 patients).

43 nd unique and may make it an ideal bone pain palliation agent.

44 The data from this review show that palliation alone generates HC similar to that from 1 deg

45 Successful palliation also appears to be related to the percentage

46 megestrol acetate provided superior anorexia palliation among advanced cancer patients compared with

47 ival and reintervention rates after stage II palliation, anatomic and physiologic variables at pre-Fo

48 imensional echocardiography (3DE) prestage 1 palliation and (2) TR is associated with reduced surviva

49 the intensive care unit, 13 (68%) initiated palliation and 5 (42%) documented code status.

50 ntinually walk a fine line between providing palliation and administering treatments that lead to exc

51 g the transition from active intervention to palliation and finally, end of life care.

52 racil-based regimens, especially in terms of palliation and functioning.

53 Pain palliation and global quality of life (QOL) were the two

54 as created a range of choices for treatment, palliation and improved life expectancy.

55 BRS decreased with previous palliation and increasing patient age.

56 herapeutic applications, including bone pain palliation and intravascular radiation therapy.

57 genital heart disease, as opposed to initial palliation and later repair, is now commonplace.

58 k 13 in pain severity and interference; pain palliation and progression at week 13; time to pain prog

59 ive procedure for select patients, providing palliation and prolonging survival.

60 additional costs for care delivered between palliation and repair (e.g., outpatient visits, cardiac

61 Liver transplantation can provide effective palliation and should be considered in carefully selecte

62 rt disease during the period between stage I palliation and stage II palliation.

63 Survival after stage II palliation and subsequent Fontan completion is equivalen

64 amic therapy using porfimer (P-PDT) improves palliation and survival in nonresectable hilar bile duct

65 Timely surgical intervention may allow palliation and the ability to pursue subsequent systemic

66 n because the parents refused univentricular palliation and the valvar anomalies precluded a Ross-Kon

67 ith significant interaction between stage of palliation and treatment group.

68 By multivariable analysis, prior palliation and younger age at repair were predictive of

69 Fifteen patients received nonsurgical palliation, and 30 patients underwent resection of their

70 alth promotion and prevention, survivorship, palliation, and bereavement.' Supportive care can be cla

71 study was to determine survival, adequacy of palliation, and complications after SEMS placement as so

72 ; other endpoints included toxicity, symptom palliation, and quality of life.

73 Results for quality of life, symptom palliation, and tolerability are presented here.

74 sectable disease, and the recent thoughts on palliation are discussed.

75 ronic heart failure that results from failed palliation are limited, in part, by the mammalian heart'

76 ior treatment, extent of tumor, and need for palliation are the most important factors in the decisio

77 Support and palliation are the only current therapies.

78 tion of newborns undergoing single-ventricle palliation are unclear.

79 trend for longer survival time, and similar palliation as with P-PDT.

80 fy risk factors for failure of cavopulmonary palliation at elevated altitude.

81 ingle-stage procedure (n=186), after initial palliation at our center (n=74), or after surgery elsewh

82 ents in the enzalutamide group reported pain palliation at week 13 versus one (7%) of 15 in the place

83 noma esophagus patients require some form of palliation because of locally advanced stage or distant

84 s with DILV or TA-TGA who underwent surgical palliation between 1983 and 2002.

85 e-ventricle physiology who underwent stage I palliation between 2004 and 2010, 75 (69%) infants (Norw

86 tatistically significant differences in pain palliation between the treatment arms.

87 several centers have performed second-stage palliation - bidirectional Glenn or hemi-Fontan procedur

88 delivery was markedly reduced in the hybrid palliation (Blalock-Tausig shunt 591, right ventricle-to

89 for massive splenomegaly (>1500 g) provides palliation but is associated with a high rate of periope

90 tion occurred frequently early after Norwood palliation but normalized with higher FiO2 or PEEP.

91 of androgen production and function provides palliation but not cure in men with prostate cancer (PCa

92 ive therapies continue to be used mostly for palliation, but have also been used with curative intent

93 long life by weeks or months and may provide palliation, but it is not curative.

94 gans, and ultimately they led to the cure or palliation by liver transplantation of more than 2 dozen

95 (e.g., familial hyperlipoproteinemia) whose palliation by portal diversion presaged definitive corre

96 In addition to surgery for cure or palliation (by excision and a variety of other cytoreduc

97 Palliation-by-death will drive us farther apart, not clo

98 is curious: Does the energy directed toward "palliation-by-death" mean that our society is more compa

99 eight at which repair or further more stable palliation can be safely achieved.

100 Previously reserved for palliation, chemotherapy is now also a central component

101 The heart team believed surgical palliation conferred high operative risk due to the pati

102 Staged palliation culminating in the Fontan procedure has resul

103 Importantly, age at Stage II palliation decreased from Era 1 to Era 3 (7.1 vs. 5.9 mo

104 y initially be limited to metastatic disease palliation, demonstration of equivalent efficacy would a

105 in tumours with current therapies limited to palliation due to therapeutic resistance.

106 complex defects that would require surgical palliation (e.g., functional univentricular heart).

107 Male sex, pulmonary atresia, and previous palliations emerged as predictors for larger AO dimensio

108 tients with HLH, it provides only short-term palliation even when combined with pulmonary artery band

109 Freedom from palliation failure, defined as death, transplant, BDG/Fo

110 s in service organization to improve patient palliation, family grieving, and allocation of ICU beds.

111 y be occasions when a strategy using initial palliation followed by later repair may seem prudent, th

112 The Fontan procedure is a successful palliation for children with single-ventricle physiology

113 High-dose 2CDA therapy provides effective palliation for CML in accelerated or blast phases, even

114 ost patients require some type of endoscopic palliation for dysphagia during the course of their illn

115 However, palliation for HLHS is a three-stage process and final j

116 Results of staged palliation for hypoplastic left heart syndrome (HLHS) ha

117 vs. balloon valvotomy, shunt type in staged palliation for hypoplastic left heart syndrome (HLHS), a

118 enting, the hybrid approach achieves stage 1 palliation for hypoplastic left heart syndrome with diff

119 n infants requiring 3-stage single-ventricle palliation for hypoplastic left heart syndrome, attritio

120 perfusion in patients undergoing first-stage palliation for hypoplastic left heart syndrome.

121 n aortic valvuloplasty; shunt type in staged palliation for hypoplastic left heart syndrome; strategi

122 ow-dose HDR brachytherapy provides excellent palliation for local control of acral CTCL lesions, offe

123 ablation and chemotherapy provide effective palliation for most patients with advanced prostate canc

124 In general, devices provide useful palliation for otherwise uncontrollable seizures, but wi

125 may become important components of improving palliation for patients with advanced disease.

126 The cornerstone of palliation for patients with R/M HNSCC is a platinum-bas

127 ontan procedure is the culmination of staged palliation for patients with univentricular physiology.

128 RECENT FINDINGS: Infants following palliation for single ventricle physiology have persiste

129 utcomes of patients undergoing cavopulmonary palliation for single ventricle physiology may be impact

130 t been the experience in newborns undergoing palliation for single-ventricle defects, in particular,

131 ot to be curative but to provide nonsurgical palliation for the symptoms of gastric or colonic obstru

132 o recovery and survival of infants following palliation for univentricular hearts.

133 tinely when a patient is undergoing surgical palliation for unresectable periampullary carcinoma.

134 nsecutive patients undergoing univentricular palliation from 1990 to 2008, predictors of mortality we

135 review of 771 patients who underwent Fontan palliation from 1992 to 2009.

136 therapy guided by ERCP may provide improved palliation from biliary obstruction in the future.

137 ith either of the Norwood models, the hybrid palliation had higher pulmonary-to-systemic flow ratio a

138 Staged surgical palliation has dramatically improved survival, yet event

139 This traditional 3-stage surgical palliation has seen several innovations in the past deca

140 prospective randomized trials of endoscopic palliation have demonstrated that late gastric outlet ob

141 t consisted of a functional single-ventricle palliation in 38 patients (83%) and biventricular repair

142 This study examined survival after surgical palliation in children with single-ventricle physiology.

143 and with improved survival after first-stage palliation in comparison with patients diagnosed after b

144 The staged palliation in HLHS may be a risk factor particularly for

145 on therapy (WBRT) offers tumor shrinking and palliation in many cases, but it has been speculated tha

146 This study evaluated endoscopic palliation in patients with hilar cholangiocarcinoma usi

147 logy, and treatment of symptoms that require palliation in patients with terminal cancer.

148 n declines) with similar global QOL and pain palliation in the MP arm.

149 val for patients with HLHS undergoing staged palliation increased significantly.

150 epilepsy, muscle spasm, alcohol withdrawal, palliation, insomnia, and sedation as they allostericall

151 h-quality cancer care include integration of palliation into cancer care, advance care planning, sent

152 Failed single-ventricle palliation is a growing indication for heart transplanta

153 Palliation is achieved by fluid drainage, but the most e

154 Very early palliation is also predicted to quickly yield near total

155 volume and flatter bending angle prestage 1 palliation is associated with TV failure at medium-term

156 plications of the stages of single ventricle palliation is critical.

157 EC) providing clinical benefit with improved palliation is highly desirable.

158 lected patients, a functional univentricular palliation is indicated in those with major straddling a

159 procedure carries high risk, and duration of palliation is poor.

160 hunt to improve survival to the second-stage palliation is unknown.

161 ry, especially after failed single-ventricle palliation, is presenting new obstacles that may start r

162 ificant morbidity and inconsistent long-term palliation; it is more appropriate in patients with a si

163 For others, palliation may be achieved through additional surgical a

164 and absent central pulmonary arteries, good palliation may be achieved, but repeated angioplasty is

165 This palliation may be intended for the life of the patient i

166 Patients who have undergone the Fontan palliation may develop ventricular dysfunction and arrhy

167 the diseased heart as an adjunct to surgical palliation may provide some benefits over surgery alone

168 s vs 47 of 163 [28.8%]; p=0.0005) and faster palliation (median time to palliation 5.6 months [95% CI

169 F with pulmonary stenosis (n=4), post-Fontan palliation (n=5), and other complex congenital heart dis

170 f intensified doxorubicin and ifosfamide for palliation of advanced soft-tissue sarcoma unless the sp

171 biliary stent is the modality of choice for palliation of biliary obstruction.

172 Palliation of bone pain can be achieved in men with andr

173 l treatment benefit compared with placebo in palliation of bone pain or reduction of SREs.

174 all survival, a decrease in skeletal events, palliation of bone pain, and a low profile of adverse re

175 rn in radioimmunotherapy and in radionuclide palliation of bone pain.

176 Progress in the palliation of bony metastases has resulted in a decrease

177 ew therapeutic approaches for prevention and palliation of cardiac disease and have raised new questi

178 t of 5-year-old children following repair or palliation of CHD.

179 ques and devices are being developed for the palliation of children with a single ventricle.

180 ssion tube allows a low-tech approach to the palliation of colonic obstruction.

181 an procedure is the definitive operation for palliation of complex congenital heart disease with sing

182 indispensable modality in the treatment and palliation of complications from pancreatic adenocarcino

183 on is a recognized complication after Fontan palliation of congenital heart disease.

184 Etanercept may be useful for palliation of constitutional symptoms in MMM.

185 offers the potential for cure, control, and palliation of disease in greater than 50% of patients wi

186 , the study also was designed to compare the palliation of disease-related symptoms.

187 Many modalities of palliation of dysphagia are available, but the procedure

188 ng results and the most suitable therapy for palliation of dysphagia in a given patient.

189 ween years 2005 and 2015 on various modes of palliation of dysphagia in carcinoma esophagus were stud

190 th least morbidity, mortality, and long-term palliation of dysphagia needs to be chosen for the patie

191 r radiotherapy or chemotherapy for long-term palliation of dysphagia with good quality of life.

192 s study aims to discuss the recent trends in palliation of dysphagia with promising results and the m

193 of SEMS (uncovered or partially covered) for palliation of extrahepatic bile duct obstruction initial

194 Endoscopic stents are placed for palliation of extrahepatic bile duct obstruction.

195 ave been multiple modifications for surgical palliation of functional single ventricle since the init

196 For endoscopic palliation of gastric outlet obstruction, enteral self-e

197 SEMS insertion for the palliation of hilar cholangiocarcinoma offers higher tec

198 Secondly, we examine new results for palliation of HLHS.

199 The first stage of surgical palliation of hypoplastic left heart syndrome (HLHS), th

200 y 4 decades ago, the progress in the 3-stage palliation of hypoplastic left heart syndrome and relate

201 First-stage palliation of hypoplastic left heart syndrome has been p

202 Palliation of intractable abdominal pain can safely be p

203 c disease and for patients with the need for palliation of local symptoms, and may be considered as a

204 (8) in metastatic disease, surgery only for palliation of major symptoms; (9) surgeons experienced i

205 xpandable metal stents (CSEMS), intended for palliation of malignant biliary obstruction, have been u

206 go to specialty in the early management and palliation of malignant bowel obstruction.

207 Metal biliary stents continue to be used for palliation of malignant distal biliary obstruction with

208 f removing gastric neoplasms, and endoscopic palliation of malignant gastric outlet obstruction via s

209 Colonic stenting was introduced for palliation of malignant large-bowel obstruction (MLBO) m

210 Palliation of malignant strictures has improved with adv

211 rd endoscopic and percutaneous approaches to palliation of malignant strictures of the bile duct.

212 iepileptic medications are commonly used for palliation of mass effect and seizures, respectively.

213 f androgen deprivation therapy (ADT) for the palliation of men with androgen-sensitive disease.

214 for treatment of benign bone tumors and for palliation of metastases involving bone and soft-tissue

215 nsistently as having low appropriateness for palliation of metastatic bony pain compared with opioid

216 Measures of delay, control, and palliation of metastatic disease such as pain response,

217 EMS seem to be an appropriate technology for palliation of oesophageal cancer in resource-limited set

218 provement in clinical symptoms and excellent palliation of pain can be achieved.

219 oablation is a safe and effective method for palliation of pain due to metastatic disease involving b

220 t are approved in the USA and Europe for the palliation of pain from metastatic bone cancer, whereas

221 iver, prostate, and brain cancer and for the palliation of pain in bone metastasis.

222 estimable], p=0.0004) and median duration of palliation of pain intensity (4.2 months [95% CI 3.0-4.9

223 Palliation of pain interference (134 of 223 [60.1%] vs 3

224 38 of 100 [38.0%], p=0.0002; median time to palliation of pain interference 1.0 months [95% CI 0.9-1

225 Endoscopic approaches for diagnosis and palliation of pancreatic adenocarcinoma are rapidly expa

226 The surgical treatment and palliation of pancreatic cancer continues to advance.

227 Vinorelbine shows promise in the palliation of patients with malignant pleural mesothelio

228 of external-beam radiotherapy (EBRT) in the palliation of posterior uveal metastases in terms of cli

229 patient received RF ablation for successful palliation of progressive follicular lymphoma adjacent t

230 egimen with an acceptable safety profile for palliation of recurrent SCCHN.

231 For patients undergoing Fontan procedures as palliation of single ventricle physiology, the addition

232 diation therapy remains the mainstay of pain palliation of solitary lesions, bone-seeking radiopharma

233 mCi) per cycle is safe and offers effective palliation of symptoms and disease stabilization in pati

234 Management is aimed at palliation of symptoms and improvement in quality of lif

235 of therapy for many patients with cancer is palliation of symptoms common at the end of life, includ

236 d therapy has primarily been oriented toward palliation of symptoms related to organ involvement.

237 o make more informed choices, achieve better palliation of symptoms, and have more opportunity to wor

238 s discerned, but most patients had effective palliation of symptoms.

239 volves either transplantation (Tx) or staged palliation of the native heart.

240 patients, 217 (93%) never required surgical palliation of their primary tumor.

241 chose among them when undertaking endoscopic palliation of this difficult and rapidly rising disease.

242 Palliation of TOF with systemic-to-pulmonary artery shun

243 Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fr

244 terial-chemo-embolization (TACE) is used for palliation of unresectable hepatocellular carcinoma (HCC

245 Hemodynamic stability after Norwood palliation often requires manipulation of pulmonary vasc

246 d with older age at the time of second-stage palliation, older age at pre-Fontan evaluation and femal

247 complex surgical atrial anatomy (ie, Fontan palliation or atrial switch procedure).

248 of LV hypoplasia, mandating single-ventricle palliation or cardiac transplantation.

249 decision making to direct care toward either palliation or more aggressive measures, such as tube fee

250 patients with LRRC treated with nonsurgical palliation or resection and identify predictors of poor

251 Patients with LRRC treated with nonsurgical palliation or resection experience significant levels of

252 of the approach, traditional surgical staged palliation or the hybrid procedure, survivals have vastl

253 Patients who received inotropes for palliation or those who preferred inotropes over LVAD ha

254 ia (P=0.003), male sex (P=0.01) and previous palliations (P=0.046) were associated with larger AO are

255 me loading throughout the surgical stages of palliation, particularly after the HF.

256 Despite significant improvements in palliation, patients' quality of life diminishes and the

257 ir of TOF, and total combined HC and LOS for palliation plus eventual repair of TOF (two-stage approa

258 with hepatic malignancies and those for whom palliation rather than long-term cure is the aim.

259 , prevention, treatment, rehabilitation, and palliation) receive them, without undue financial hardsh

260 Patients treated with nonsurgical palliation reported moderate to severe pain beyond the t

261 whether the type of shunt used at stage one palliation (S1P) affected the survival and the periopera

262 Outcome of stage 1 palliation (S1P) for hypoplastic left heart syndrome (HL

263 Survival to stage 2 palliation (S2P) was also significantly improved in the

264 The effect of the timing of stage 2 palliation (S2P), a physician-modifiable factor, on long

265 eart syndrome who underwent stage I surgical palliation (Sano: 11; Norwood: 73; Hybrid: 54) between 2

266 ment regarding the best strategy for stage I palliation should be reserved for an analysis of post-Fo

267 12 patients early (</=3 days) after Norwood palliation, simultaneous arterial, superior vena caval (

268 ng and mechanisms of myocardial injury among palliation strategies do not affect outcomes.

269 Surgical palliation strategies were not identified as risk factor

270 All 3 palliation strategies, Norwood, Sano, and Hybrid, curren

271 dysfunction, and AVVR were equivalent among palliation strategies.

272 Surgical palliation strategy does not affect mortality, interstag

273 urvival and freedom from AVVR, regardless of palliation strategy.

274 While chemotherapy can achieve significant palliation, surgery may have a potential impact on long-

275 poplasia who have undergone single-ventricle palliation (SVP).

276 on and mortality, particularly after initial palliation to delay complete repair.

277 targeted therapy to progress beyond symptom palliation to early intervention for survival gain.

278 Surgical palliation to relieve systemic outflow obstruction is no

279 e intensive care unit, three (37%) initiated palliation, two (25%) documented the patient's code stat

280 rapy, supportive care drugs, and opioids for palliation uniformly available.

281 Stage II palliation was achieved in 92 (67%) patients (Sano: 7; N

282 Pain palliation was assessed in patients who had clinically s

283 3-dimensional computational model of hybrid palliation was developed by the finite volume method, al

284 Freedom from death/transplant after stage II palliation was equivalent between the groups (Norwood, 8

285 Pain palliation was observed with all three doses levels.

286 The reasons for palliation were severe HS at time of presentation (two p

287 d, n=32) who subsequently underwent stage II palliation were studied.

288 rior to planned resection; and as a means of palliation when tumors are incurable.

289 landmark of progress in non-chemotherapeutic palliation, when clearly we have not.

290 t stents are the first choice of therapy for palliation, which is safe and cost-effective, and they c

291 ral effusions is primarily directed at local palliation with a wide variety of sclerosing agents, of

292 iation of systemic hypoxia, and avoidance of palliation with an arteriopulmonary shunt.

293 l-dependent pulmonary blood flow may undergo palliation with either a patent ductus arteriosus (PDA)

294 alternative to a surgical shunt for neonatal palliation with evidence for greater postprocedural stab

295 econstruction provide effective intermediate palliation with excellent late survival.

296 some nonchemotherapy treatments may provide palliation with few side effects.

297 Vinblastine provides effective palliation with low toxicity in recurrent Hodgkin's dise

298 Palliation with platinum agent remains the standard of c

299 malignant adrenal tumors, both for cure and palliation, with low morbidity and mortality.

300 rtic homograft valve in the conduit, stage I palliation within the first year of our experience, and